Floatz logo

Cldn6 Car-T

Extragonadal Germ Cell Tumor

BioNTech SECell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Extragonadal Germ Cell Tumor cohort.

Asset / SponsorPhaseRating
FILGRASTIM
City of Hope Medical Center
Phase 2BBB
ETOPOSIDE
City of Hope Medical Center
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Memorial Sloan Kettering Cancer Center
Phase 3BB
Carboplatin
City of Hope Medical Center
Phase 3BB
Cyclophosphamide
UNICANCER
Phase 2BB

View all 34 →

Same molecule, other indications

Cldn6 Car-T is also rated in:

testicular germ cell tumorDormant
CCC
Indicative ·
53 / 100
View asset →
neoplasmDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →